• Cycloheximide, RBMS1 and Evidence Boundaries

  2026-10-11

  The supplied 2022 study supports a mechanistic model in which RBMS1 influences PD-L1 stability and immune activity in triple-negative breast cancer, but it does not establish a Cycloheximide-specific result or clinical benefit. Product-page claims about Cycloheximide provide context rather than independent evidence.

• From Glucose Uptake to Ferroptosis Insight

  2026-10-10

  A translational perspective on connecting 2-NBDG fluorescence, glucose transporter activity, lipid remodeling, and sorafenib resistance in hepatocellular carcinoma.

• Cisapride (R 51619): Translational Cardiac Insight

  2026-10-09

  Cisapride offers a useful conceptual bridge between 5-HT4 pharmacology, hERG channel inhibition, and human iPSC-derived cardiomyocyte phenotyping. This thought-leadership article examines how translational researchers can interpret that dual biology without confusing mechanistic evidence with clinical prediction.

• Carbapenemase Transmission in CREC Hospitals

  2026-10-09

  Chen et al. examined 54 carbapenem-resistant Enterobacter cloacae isolates from eight teaching hospitals in Guangdong, combining carbapenemase-gene localization, susceptibility testing, transfer analysis, mobile-element profiling, and strain typing. The study links predominantly plasmid-associated blaNDM-1 with multidrug resistance and substantial dissemination potential, while also showing why regional surveillance findings should not be treated as direct evidence of clinical treatment effectiveness.

• Pomalidomide (CC-4047) in Myeloma Research

  2026-10-08

  Pomalidomide (CC-4047) is relevant to hematological malignancy research, but the supplied peer-reviewed study does not directly test it. Instead, the study provides a genomic framework for interpreting drug-response variation across multiple myeloma cell lines and clarifies why model selection, molecular heterogeneity, and independent validation matter.

• CAPE and Fyn–Stat3 Neurodegeneration Research

  2026-10-08

  A source-grounded overview of Caffeic Acid Phenethyl Ester (CAPE), its reported NF-κB-related activity, and how it may be studied conceptually alongside Fyn–Stat3 neurodegeneration findings in zebrafish. The article separates supplier-reported observations from peer-reviewed evidence and defines key limitations.

• Cy5 Secondary Antibody in Bone Regeneration Research

  2026-10-07

  This overview places the Cy5 Goat Anti-Mouse IgG (H+L) Antibody in the context of a 2024 preclinical study on lithium-engineered BMSC exosomes, Wnt10a signaling, and bone repair. It separates the study’s biological findings from supplier-reported reagent characteristics and explains what can—and cannot—be concluded about fluorescent detection, evidence strength, and translational relevance.

• Cy5 Secondary Antibody in Ferritin Vaccine Research

  2026-10-07

  A source-grounded overview of how Cy5 fluorescent detection can conceptually support mouse antibody measurements in ferritin-based vaccine research, while distinguishing reported findings from assay interpretation and product information.

• DiscoveryProbe FDA-approved Drug Library: Evidence

  2026-10-06

  A source-grounded guide to how FRET and stress-granule readouts support viral protease inhibitor screening, what the evidence shows, and where a repurposing library can—and cannot—support interpretation.

• CGP 55845 Hydrochloride in GABAB Research

  2026-10-06

  CGP 55845 hydrochloride provides a pharmacological lens for separating GABAB receptor signaling from astrocytic GAT-3 mechanisms. This article interprets its reported activity alongside dentate gyrus findings while emphasizing evidence boundaries, assay context, and translational limitations.

• Lithium, Exosomal Wnt10a, and Osteogenesis

  2026-10-05

  This 2024 ACS Applied Materials & Interfaces study identifies a mechanistic link between lithium exposure, Rab11a-dependent exosomal Wnt10a secretion, and β-catenin activation in bone mesenchymal stem cells. Its comparative cell, vesicle, and animal evidence suggests that lithium-engineered exosomes and GelMA-based delivery systems may improve bone regeneration, while remaining preclinical and subject to important translational limitations.

• Fingolimod and In Vivo CAR-T-Mimic Research

  2026-10-05

  Fingolimod (FTY720) is an established S1P receptor modulator and immunomodulatory agent for multiple sclerosis, whereas magnetic CAR-T-mimicking cells remain a preclinical solid-tumor strategy. This overview compares their evidence, explains where S1P-dependent lymphocyte trafficking may affect interpretation, and emphasizes that no supplied study validates Fingolimod as part of the magnetic nano-antibody system.

• LY2603618: Chk1 Inhibition and Research Evidence

  2026-10-04

  LY2603618 is described by APExBIO as a selective Chk1 inhibitor for research into DNA damage response and cell-cycle regulation. This overview separates supplier claims from the peer-reviewed evidence, with particular attention to PPP2R2A-associated sensitivity in high-grade serous ovarian cancer, biomarker development, chemotherapy-sensitization concepts, and the limitations of current preclinical data.

• Marein Inhibits ABCG2 and Restores Chemosensitivity

  2026-10-03

  A 2024 Biochemical Pharmacology study identifies marein, a flavonoid from Coreopsis tinctoria Nutt, as a competitive inhibitor of the ABCG2 drug-efflux transporter. The work links transporter inhibition to increased intracellular exposure to several ABCG2-substrate chemotherapeutics and to restored drug sensitivity in resistant cancer-cell models, while also proposing F439 as a relevant interaction site.

• Z-VAD-FMK in Redox-Barrier Apoptosis Studies

  2026-10-02

  Z-VAD-FMK provides a causal way to test whether caspases connect oxidative stress with epithelial barrier failure. This article translates OXER1 redox biology into a rigorous apoptosis-inhibition assay strategy while distinguishing caspase-dependent injury from inflammation and non-apoptotic damage.

8121 records 1/542 page Next 12345 下5页 Last page